|
gptkbp:instance_of
|
gptkb:smartphone
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Nant_Kwest
|
|
gptkbp:activities
|
tumor cells
|
|
gptkbp:can_be_extended_by
|
gptkb:organization
|
|
gptkbp:can_create
|
cytokines
C D25
NK G2 D receptor
|
|
gptkbp:developed_by
|
gptkb:Yoshihiro_Takeda
|
|
gptkbp:established
|
IL-12
|
|
gptkbp:exhibits
|
cytotoxicity
|
|
gptkbp:genetic_diversity
|
transfection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NK-92 cells
|
|
gptkbp:is_characterized_by
|
C D16 expression
C D56 expression
lack of T-cell markers
|
|
gptkbp:is_designed_to
|
chimeric antigen receptors (CA Rs)
|
|
gptkbp:is_studied_in
|
natural killer cell biology
|
|
gptkbp:is_used_in
|
clinical trials
adoptive cell transfer therapy
|
|
gptkbp:language
|
RPMI-1640 medium
|
|
gptkbp:origin
|
gptkb:Person
|
|
gptkbp:produced_by
|
a patient with non-Hodgkin lymphoma
|
|
gptkbp:requires
|
IL-2 for growth
|
|
gptkbp:sensor
|
certain chemotherapeutic agents
|
|
gptkbp:storage
|
liquid nitrogen
|
|
gptkbp:targets
|
HLA-negative tumors
|
|
gptkbp:travel_time
|
24 hours
|
|
gptkbp:type
|
natural killer cell
|
|
gptkbp:used_in
|
cancer immunotherapy
|